Condition 1: stroke. Condition 2: neurogenic bladder. Cerebrovascular disease, unspecified Neuromuscular dysfunction of bladder, unspecified
Conditions
Interventions
Intervention 1: Intervention group 1, antimuscarinic drug approved in OAB treatment, Solifenacin: this group of patients will be treated with oral solifenacin 10mg tablet daily for 30 days. In this wa
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Stroke diagnosis patients Normal cognitive function Lower urinary tract symptomes Patients with CVA should be ambulatory, able to communicate, and record a voiding diary age =18 years
Exclusion criteria
Exclusion criteria: Evidence of brain stem or bilateral signs on examination Mental disorders according to the patient's own statement Having history of LUTS surgery, pelvic and urologic surgery, or trauma Other severe neurological disease including dementia Severe psychiatric disease Prostate cancer Patients who refuse consent Abnormal liver function severe constipation patiensts with previous history of hypersensitivity reaction to anticholinergics or closed anterior chamber glaucoma
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NBSS score. Timepoint: begining of study and 4 weeks after intervention. Method of measurement: questionnaire.;ICIQ-UI score. Timepoint: begining of study and 4 weeks after intervention. Method of measurement: questionnaire.;I-QOL test score. Timepoint: begining of study and 4 weeks after intervention. Method of measurement: questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Pormohammad
Tabriz University of Medical Sciences
Outcome results
None listed